-
2
-
-
0026716425
-
Revisiting some factors contributing to variability
-
Gibaldi M. Revisiting some factors contributing to variability. Ann Pharmacother 1992; 26 (7/8): 1002-7
-
(1992)
Ann Pharmacother
, vol.26
, Issue.7-8
, pp. 1002-1007
-
-
Gibaldi, M.1
-
3
-
-
0029743058
-
Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
-
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14 (9): 2590-611
-
(1996)
J Clin Oncol
, vol.14
, Issue.9
, pp. 2590-2611
-
-
Gurney, H.1
-
4
-
-
0023618618
-
Therapeutic drug monitoring in oncology: Problems and potential in antineoplastic therapy
-
Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205-27
-
(1987)
Clin Pharmacokinet
, vol.13
, pp. 205-227
-
-
Moore, M.J.1
Erlichman, C.2
-
5
-
-
0001865992
-
Methotrexate
-
Evans WE, Schentag JJ, Jusko WJ, editors. Vancouver (WA) Applied Therapeutics Inc.
-
Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA) Applied Therapeutics Inc., 1992: 29.1-29.42
-
(1992)
Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd Ed.
-
-
Crom, W.R.1
Evans, W.E.2
-
7
-
-
0034056182
-
Adaptive control methods for the dose individualisation of anticancer agents
-
Rousseau A, Marquet P, Debord J, et al. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38 (4): 315-53
-
(2000)
Clin Pharmacokinet
, vol.38
, Issue.4
, pp. 315-353
-
-
Rousseau, A.1
Marquet, P.2
Debord, J.3
-
8
-
-
0024360395
-
Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
-
Evans W, Relling M. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327-36
-
(1989)
Clin Pharmacokinet
, vol.16
, pp. 327-336
-
-
Evans, W.1
Relling, M.2
-
9
-
-
0025873389
-
Pharmacokinetic optimisation of anti-cancer therapy
-
Liliemark J, Peterson C. Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 1991; 21 (3): 213-31
-
(1991)
Clin Pharmacokinet
, vol.21
, Issue.3
, pp. 213-231
-
-
Liliemark, J.1
Peterson, C.2
-
11
-
-
0030749434
-
Therapeutic drug monitoring opportunities in cancer therapy
-
McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997; 74 (1): 39-54
-
(1997)
Pharmacol Ther
, vol.74
, Issue.1
, pp. 39-54
-
-
McLeod, H.L.1
-
12
-
-
0027429687
-
Therapeutic drug monitoring in cancer management
-
Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem 1993; 39 (11B): 2419-30
-
(1993)
Clin Chem
, vol.39
, Issue.11 B
, pp. 2419-2430
-
-
Galpin, A.J.1
Evans, W.E.2
-
13
-
-
0030892991
-
Pharmacokinetic optimization of cancer chemotherapy: Effect on outcomes
-
Masson E, Zamboni WC. Pharmacokinetic optimization of cancer chemotherapy: effect on outcomes. Clin Pharmacokinet 1997; 32 (4): 324-43
-
(1997)
Clin Pharmacokinet
, vol.32
, Issue.4
, pp. 324-343
-
-
Masson, E.1
Zamboni, W.C.2
-
14
-
-
0003136034
-
Individualized dosing of anti-cancer drugs and the role of therapeutic monitoring
-
Grochow LB, Ames MM, editors. Baltimore (MD): Williams & Wilkins
-
Grochow LB. Individualized dosing of anti-cancer drugs and the role of therapeutic monitoring. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore (MD): Williams & Wilkins, 1998: 3-16
-
(1998)
A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics
, pp. 3-16
-
-
Grochow, L.B.1
-
15
-
-
0343090967
-
Making TDM work to optimize cancer chemotherapy: A multidisciplinary team approach
-
Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44 (2): 388-400
-
(1998)
Clin Chem
, vol.44
, Issue.2
, pp. 388-400
-
-
Hon, Y.Y.1
Evans, W.E.2
-
16
-
-
0027787737
-
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
-
Workman P, Graham MA, editors. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press
-
Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. In: Workman P, Graham MA, editors. Pharmacokinetics and cancer chemotherapy. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1993: 51-78
-
(1993)
Pharmacokinetics and Cancer Chemotherapy
, pp. 51-78
-
-
Kobayashi, K.1
Jodrell, D.I.2
Ratain, M.J.3
-
17
-
-
0036399707
-
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs
-
Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16: 253-62
-
(2002)
Fundam Clin Pharmacol
, vol.16
, pp. 253-262
-
-
Rousseau, A.1
Marquet, P.2
-
18
-
-
0027418925
-
Individualizing dosing of cancer chemotherapy
-
Kobayashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993; 20 (1): 30-42
-
(1993)
Semin Oncol
, vol.20
, Issue.1
, pp. 30-42
-
-
Kobayashi, K.1
Ratain, M.J.2
-
19
-
-
0032422726
-
Practical treatment guide for dose individualisation in cancer chemotherapy
-
Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56 (6): 1019-38
-
(1998)
Drugs
, vol.56
, Issue.6
, pp. 1019-1038
-
-
Canal, P.1
Chatelut, E.2
Guichard, S.3
-
20
-
-
0034851530
-
Therapeutic drug monitoring for cytotoxic drugs
-
Lennard L. Therapeutic drug monitoring for cytotoxic drugs. Br J Clin Pharmacol 2001; 52: 75-87S
-
(2001)
Br J Clin Pharmacol
, vol.52
-
-
Lennard, L.1
-
21
-
-
0028342646
-
Individual dose adaptation of anticancer drugs
-
Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994; 30A (6): 844-51
-
(1994)
Eur J Cancer
, vol.30 A
, Issue.6
, pp. 844-851
-
-
Desoize, B.1
Robert, J.2
-
22
-
-
0034971415
-
Concentration-controlled or effect-controlled trials: Useful alternatives to conventional dose-controlled trials?
-
Grahnen A, Karlsson MO. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 2001; 40 (5): 317-25
-
(2001)
Clin Pharmacokinet
, vol.40
, Issue.5
, pp. 317-325
-
-
Grahnen, A.1
Karlsson, M.O.2
-
23
-
-
0027323727
-
Busulphan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
-
Grochow LB. Busulphan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (4) Suppl. 4: 18-25
-
(1993)
Semin Oncol
, vol.20
, Issue.4 SUPPL. 4
, pp. 18-25
-
-
Grochow, L.B.1
-
24
-
-
13344259305
-
Association of busulphan area under the curve with veno-occlusive disease following BMT
-
Dix SP, Wingard JR, Mullins RE, et al. Association of busulphan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17 (2): 225-30
-
(1996)
Bone Marrow Transplant
, vol.17
, Issue.2
, pp. 225-230
-
-
Dix, S.P.1
Wingard, J.R.2
Mullins, R.E.3
-
25
-
-
0029866142
-
Busulphan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulphan based on targeted plasma levels
-
Demirer T, Buckner CD, Appelbaum FR, et al. Busulphan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulphan based on targeted plasma levels. Bone Marrow Transplant 1996; 17 (4): 491-5
-
(1996)
Bone Marrow Transplant
, vol.17
, Issue.4
, pp. 491-495
-
-
Demirer, T.1
Buckner, C.D.2
Appelbaum, F.R.3
-
26
-
-
0029927901
-
Busulphan, cyclophosphamide and fractionated total body irradiation for allogenic marrow transplantation for advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulphan based on targeted plasma levels
-
Demirer T, Buckner CD, Appelbaum FR, et al. Busulphan, cyclophosphamide and fractionated total body irradiation for allogenic marrow transplantation for advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulphan based on targeted plasma levels. Bone Marrow Transplant 1996; 17 (3): 341-6
-
(1996)
Bone Marrow Transplant
, vol.17
, Issue.3
, pp. 341-346
-
-
Demirer, T.1
Buckner, C.D.2
Appelbaum, F.R.3
-
27
-
-
0030818478
-
An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children
-
Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20 (5): 347-54
-
(1997)
Bone Marrow Transplant
, vol.20
, Issue.5
, pp. 347-354
-
-
Chattergoon, D.S.1
Saunders, E.F.2
Klein, J.3
-
28
-
-
0008014475
-
Pharmacodynamic, pharmacokinetic and plasma monitoring of busulphan in pediatric patients undergoing bone marrow transplantation
-
Regazzi MB, Locatelli F, Buggia I, et al. Pharmacodynamic, pharmacokinetic and plasma monitoring of busulphan in pediatric patients undergoing bone marrow transplantation [abstract]. Ther Drug Monit 1997; 19: 597
-
(1997)
Ther Drug Monit
, vol.19
, pp. 597
-
-
Regazzi, M.B.1
Locatelli, F.2
Buggia, I.3
-
29
-
-
4243881136
-
Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease
-
Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract]. Blood 1999; 94: 145a
-
(1999)
Blood
, vol.94
-
-
Bolinger, A.M.1
Zangwill, A.B.2
Slattery, J.T.3
-
30
-
-
0033832458
-
Individualising high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
-
Tran HT, Madden T, Petropoulos D, et al. Individualising high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26 (5): 463-70
-
(2000)
Bone Marrow Transplant
, vol.26
, Issue.5
, pp. 463-470
-
-
Tran, H.T.1
Madden, T.2
Petropoulos, D.3
-
31
-
-
0030998359
-
A Bayesian dosing method for carboplatin given by continuous infusion for 120h
-
Guillet P, Monjanel S, Nicoara A, et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120h. Cancer Chemother Pharmacol 1997; 40 (2): 143-9
-
(1997)
Cancer Chemother Pharmacol
, vol.40
, Issue.2
, pp. 143-149
-
-
Guillet, P.1
Monjanel, S.2
Nicoara, A.3
-
32
-
-
0030985776
-
Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer
-
Johansen MJ, Madden T, Mehra RC, et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997; 15 (4): 1481-91
-
(1997)
J Clin Oncol
, vol.15
, Issue.4
, pp. 1481-1491
-
-
Johansen, M.J.1
Madden, T.2
Mehra, R.C.3
-
33
-
-
0033975709
-
A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage
-
Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36 (2): 264-9
-
(2000)
Eur J Cancer
, vol.36
, Issue.2
, pp. 264-269
-
-
Chatelut, E.1
Pivot, X.2
Otto, J.3
-
34
-
-
13244286080
-
Optimization of high dose carboplatin treatment in children with stage IV soft tissue sarcoma (SIOP/UKCCSG MMT 98 study) by real-time pharmacokinetic monitoring
-
Veal GJ, Foot A, McDowell H, et al. Optimization of high dose carboplatin treatment in children with stage IV soft tissue sarcoma (SIOP/UKCCSG MMT 98 study) by real-time pharmacokinetic monitoring [abstract]. Proc Am Assoc Cancer Res 2002; 43: 275
-
(2002)
Proc Am Assoc Cancer Res
, vol.43
, pp. 275
-
-
Veal, G.J.1
Foot, A.2
McDowell, H.3
-
35
-
-
0013637687
-
Evaluation prospective d'une méthode d'adaptation de posologie du cisplatine
-
Desoize B, Dumont P, Manot L, et al. Evaluation prospective d'une méthode d'adaptation de posologie du cisplatine [abstract]. Bull Cancer 1995; 82: 411
-
(1995)
Bull Cancer
, vol.82
, pp. 411
-
-
Desoize, B.1
Dumont, P.2
Manot, L.3
-
36
-
-
0034843961
-
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer
-
Schellens JHM, Planting AS, Ma J, et al. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 2001; 12 (8): 667-75
-
(2001)
Anticancer Drugs
, vol.12
, Issue.8
, pp. 667-675
-
-
Schellens, J.H.M.1
Planting, A.S.2
Ma, J.3
-
37
-
-
0021847172
-
Pharmacologically directed Ara-C therapy for refractory leukemia
-
Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed Ara-C therapy for refractory leukemia. Semin Oncol 1985; 12 (2) Suppl. 3: 20-30
-
(1985)
Semin Oncol
, vol.12
, Issue.2 SUPPL. 3
, pp. 20-30
-
-
Plunkett, W.1
Iacoboni, S.2
Estey, E.3
-
38
-
-
0024589605
-
Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability
-
Ratain MJ, Schilski RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharm Ther 1989; 45 (3): 226-33
-
(1989)
Clin Pharm Ther
, vol.45
, Issue.3
, pp. 226-233
-
-
Ratain, M.J.1
Schilski, R.L.2
Choi, K.E.3
-
39
-
-
0025744506
-
Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity
-
Ratain MJ, Mick R, Schilsky RL, et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991; 9 (8): 1480-6
-
(1991)
J Clin Oncol
, vol.9
, Issue.8
, pp. 1480-1486
-
-
Ratain, M.J.1
Mick, R.2
Schilsky, R.L.3
-
40
-
-
2642572069
-
Disposition of etoposide (VP-16) in children with acute nonlymphocytic leukemia (ANLL)
-
Madden T, Crom WR, Mirro J. Disposition of etoposide (VP-16) in children with acute nonlymphocytic leukemia (ANLL) [abstract]. Clin Pharmacol Ther 1990; 47: 206
-
(1990)
Clin Pharmacol Ther
, vol.47
, pp. 206
-
-
Madden, T.1
Crom, W.R.2
Mirro, J.3
-
41
-
-
0029935554
-
Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer
-
Ando Y, Minami H, Saka H, et al. Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Jpn J Cancer Res 1996; 87 (2): 200-5
-
(1996)
Jpn J Cancer Res
, vol.87
, Issue.2
, pp. 200-205
-
-
Ando, Y.1
Minami, H.2
Saka, H.3
-
42
-
-
0029789372
-
Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer
-
Ando Y, Minami H, Saka H, et al. Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. Jpn J Cancer Res 1996; 87 (8): 856-61
-
(1996)
Jpn J Cancer Res
, vol.87
, Issue.8
, pp. 856-861
-
-
Ando, Y.1
Minami, H.2
Saka, H.3
-
43
-
-
8944246796
-
Therapeutic drug monitoring of continuous infusion etoposide in small-cell lung cancer
-
Joel SP, Ellis P, O'Byrne K, et al. Therapeutic drug monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol 1996; 14 (6): 1903-12
-
(1996)
J Clin Oncol
, vol.14
, Issue.6
, pp. 1903-1912
-
-
Joel, S.P.1
Ellis, P.2
O'Byrne, K.3
-
44
-
-
0030480554
-
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study
-
Porter D, Boddy A, Thomas H, et al. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Semin Oncol 1996; 23 (6) Suppl. 13: 34-44
-
(1996)
Semin Oncol
, vol.23
, Issue.6 SUPPL. 13
, pp. 34-44
-
-
Porter, D.1
Boddy, A.2
Thomas, H.3
-
45
-
-
0031743076
-
A randomised, concentration-controlled, comparison of standard (5-day) vs prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer
-
Joel S, O'Byrne K, Penson R, et al. A randomised, concentration- controlled, comparison of standard (5-day) vs prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann Oncol 1998; 9: 1205-11
-
(1998)
Ann Oncol
, vol.9
, pp. 1205-1211
-
-
Joel, S.1
O'Byrne, K.2
Penson, R.3
-
46
-
-
0031744483
-
Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer
-
Miller AA, Tolley EA, Niell HB. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin Cancer Res 1998; 4 (7): 1705-10
-
(1998)
Clin Cancer Res
, vol.4
, Issue.7
, pp. 1705-1710
-
-
Miller, A.A.1
Tolley, E.A.2
Niell, H.B.3
-
47
-
-
0031775809
-
A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children
-
Lowis SP, Price L, Pearson ADJ, et al. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. Br J Cancer 1998; 77 (12): 2318-23
-
(1998)
Br J Cancer
, vol.77
, Issue.12
, pp. 2318-2323
-
-
Lowis, S.P.1
Price, L.2
Pearson, A.D.J.3
-
48
-
-
0036890583
-
Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring
-
Ciccolini J, Monjanel-Mouterde S, Bun SS, et al. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit 2002; 24 (6): 709-14
-
(2002)
Ther Drug Monit
, vol.24
, Issue.6
, pp. 709-714
-
-
Ciccolini, J.1
Monjanel-Mouterde, S.2
Bun, S.S.3
-
49
-
-
0024512054
-
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
-
Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59 (2): 287-90
-
(1989)
Br J Cancer
, vol.59
, Issue.2
, pp. 287-290
-
-
Santini, J.1
Milano, G.2
Thyss, A.3
-
50
-
-
0027278648
-
Surveillance pharmacokinétique avec adaptation de posologie du 5-fluorouracile administré en perfusion continue
-
Wihlm J, Levêque D, Velten M, et al. Surveillance pharmacokinétique avec adaptation de posologie du 5-fluorouracile administré en perfusion continue. Bull Cancer 1993; 80: 439-45
-
(1993)
Bull Cancer
, vol.80
, pp. 439-445
-
-
Wihlm, J.1
Levêque, D.2
Velten, M.3
-
51
-
-
0028568929
-
Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: Preliminary results
-
Fety R, Rolland F, Barberi-Heyob M, et al. Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res 1994; 14 (6A): 2347-52
-
(1994)
Anticancer Res
, vol.14
, Issue.6 A
, pp. 2347-2352
-
-
Fety, R.1
Rolland, F.2
Barberi-Heyob, M.3
-
52
-
-
0031696544
-
Clinical impact of pharmacokinetically guided adaptation of 5-fluorouracil: Results from a multicentre, randomized trial in patients with locally advanced head and neck carcinomas
-
Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically guided adaptation of 5-fluorouracil: results from a multicentre, randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4 (9): 2039-45
-
(1998)
Clin Cancer Res
, vol.4
, Issue.9
, pp. 2039-2045
-
-
Fety, R.1
Rolland, F.2
Barberi-Heyob, M.3
-
53
-
-
0031901763
-
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
-
Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16 (4): 1470-8
-
(1998)
J Clin Oncol
, vol.16
, Issue.4
, pp. 1470-1478
-
-
Gamelin, E.1
Boisdron-Celle, M.2
Delva, R.3
-
54
-
-
0000020241
-
Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area
-
Gamelin E, Jacob J, Danquechin-Dorval E, et al. Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area [abstract]. Proc Am Soc Clin Oncol 1998; 17: 1039
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
, pp. 1039
-
-
Gamelin, E.1
Jacob, J.2
Danquechin-Dorval, E.3
-
55
-
-
0032800786
-
Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: A feasibility study in patients with advanced colorectal cancer
-
Ychou M, Duffour J, Pinguet F, et al. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res 1999; 19 (3B): 2229-36
-
(1999)
Anticancer Res
, vol.19
, Issue.3 B
, pp. 2229-2236
-
-
Ychou, M.1
Duffour, J.2
Pinguet, F.3
-
56
-
-
0026633228
-
Pharmacokinetically guided dosing of intravenous melphalan: A pilot study in patients with advanced ovarian adenocarcinoma
-
Ploin DY, Tranchand B, Guastalla JP, et al. Pharmacokinetically guided dosing of intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28A (8/9): 1311-5
-
(1992)
Eur J Cancer
, vol.28 A
, Issue.8-9
, pp. 1311-1315
-
-
Ploin, D.Y.1
Tranchand, B.2
Guastalla, J.P.3
-
57
-
-
0024831255
-
Individualisation de posologie de methotrexate haute dose par le dosage des concentrations plasmatiques interet therapeutique dans le sarcome osteohenique
-
Delepine N, Desbois JC, Delepine G, et al. Individualisation de posologie de methotrexate haute dose par le dosage des concentrations plasmatiques interet therapeutique dans le sarcome osteohenique. Bull Cancer 1989; 76: 913-8
-
(1989)
Bull Cancer
, vol.76
, pp. 913-918
-
-
Delepine, N.1
Desbois, J.C.2
Delepine, G.3
-
58
-
-
0029009264
-
Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma
-
Delepine N, Delepine G, Cornille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15 (2): 489-94
-
(1995)
Anticancer Res
, vol.15
, Issue.2
, pp. 489-494
-
-
Delepine, N.1
Delepine, G.2
Cornille, H.3
-
59
-
-
0028157622
-
Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma
-
Pignon T, Lacarelle B, Duffaud F, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420-4
-
(1994)
Cancer Chemother Pharmacol
, vol.33
, pp. 420-424
-
-
Pignon, T.1
Lacarelle, B.2
Duffaud, F.3
-
60
-
-
0029125490
-
Dosage adjustment of high-dose methotrexate using Bayesian estimation: A comparative study of two different concentrations at the end of 8-h infusions
-
Pignon T, Lacarelle B, Duffaud F, et al. Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit 1995; 17 (5): 471-8
-
(1995)
Ther Drug Monit
, vol.17
, Issue.5
, pp. 471-478
-
-
Pignon, T.1
Lacarelle, B.2
Duffaud, F.3
-
61
-
-
0033621556
-
Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia
-
Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 2000; 14 (2): 221-5
-
(2000)
Leukemia
, vol.14
, Issue.2
, pp. 221-225
-
-
Wall, A.M.1
Gajjar, A.2
Link, A.3
-
62
-
-
0024365297
-
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580)
-
Conley BA, Forrest A, Egorin MJ, et al. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 1989; 49 (12): 3436-40
-
(1989)
Cancer Res
, vol.49
, Issue.12
, pp. 3436-3440
-
-
Conley, B.A.1
Forrest, A.2
Egorin, M.J.3
-
64
-
-
0026695414
-
Hexamethylene bisacetamide in myelodysplastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations
-
Rowinsky EK, Conley BA, Jones RJ, et al. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 1992; 6 (6): 526-34
-
(1992)
Leukemia
, vol.6
, Issue.6
, pp. 526-534
-
-
Rowinsky, E.K.1
Conley, B.A.2
Jones, R.J.3
-
65
-
-
0032999140
-
Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias
-
Woo MH, Relling MV, Sonnichsen DS, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5 (3): 543-9
-
(1999)
Clin Cancer Res
, vol.5
, Issue.3
, pp. 543-549
-
-
Woo, M.H.1
Relling, M.V.2
Sonnichsen, D.S.3
-
66
-
-
0027132214
-
Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer
-
Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 1994; 12 (1): 166-75
-
(1994)
J Clin Oncol
, vol.12
, Issue.1
, pp. 166-175
-
-
Jodrell, D.I.1
Reyno, L.M.2
Sridhara, R.3
-
67
-
-
0028241397
-
Adaptive control with feedback of suramin using intermittent infusions
-
Figg WD, Stevens JA, Cooper MR. Adaptive control with feedback of suramin using intermittent infusions. J Clin Oncol 1994; 12 (7): 1523-4
-
(1994)
J Clin Oncol
, vol.12
, Issue.7
, pp. 1523-1524
-
-
Figg, W.D.1
Stevens, J.A.2
Cooper, M.R.3
-
68
-
-
0029983725
-
Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
-
Rosen PJ, Mendoza EF, Landaw EM, et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 1996; 14 (5): 1626-36
-
(1996)
J Clin Oncol
, vol.14
, Issue.5
, pp. 1626-1636
-
-
Rosen, P.J.1
Mendoza, E.F.2
Landaw, E.M.3
-
69
-
-
0027477057
-
Escalating teniposide systemic exposure to increase dose intensity for pediatric patients
-
Rodman JH, Furman WL, Sunderland M, et al. Escalating teniposide systemic exposure to increase dose intensity for pediatric patients. J Clin Oncol 1993; 11 (2): 287-93
-
(1993)
J Clin Oncol
, vol.11
, Issue.2
, pp. 287-293
-
-
Rodman, J.H.1
Furman, W.L.2
Sunderland, M.3
-
70
-
-
0029991006
-
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia
-
Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14 (5): 1504-11
-
(1996)
J Clin Oncol
, vol.14
, Issue.5
, pp. 1504-1511
-
-
Furman, W.L.1
Baker, S.D.2
Pratt, C.B.3
-
71
-
-
0036187723
-
Individual adaptive dosing of topotecan in ovarian cancer
-
Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002; 8 (2): 394-9
-
(2002)
Clin Cancer Res
, vol.8
, Issue.2
, pp. 394-399
-
-
Montazeri, A.1
Culine, S.2
Laguerre, B.3
-
72
-
-
0025279445
-
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients
-
Rodman JH, Sunderland M, Kavanagh RL, et al. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Cancer Res 1990; 50 (14): 4267-71
-
(1990)
Cancer Res
, vol.50
, Issue.14
, pp. 4267-4271
-
-
Rodman, J.H.1
Sunderland, M.2
Kavanagh, R.L.3
-
73
-
-
0025856668
-
Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia
-
Evans WE, Rodman J, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991; 28 (3) Suppl. 4: 15-21
-
(1991)
Semin Hematol
, vol.28
, Issue.3 SUPPL. 4
, pp. 15-21
-
-
Evans, W.E.1
Rodman, J.2
Relling, M.V.3
-
74
-
-
0032545976
-
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
-
Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338 (8); 499-505
-
(1998)
N Engl J Med
, vol.338
, Issue.8
, pp. 499-505
-
-
Evans, W.E.1
Relling, M.V.2
Rodman, J.H.3
-
75
-
-
0025043402
-
Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside
-
Heinemann V, Jehn U. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Leukemia 1990; 4(11): 790-6
-
(1990)
Leukemia
, vol.4
, Issue.11
, pp. 790-796
-
-
Heinemann, V.1
Jehn, U.2
-
76
-
-
0030038773
-
Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors
-
Schellens JHM, Ma J, Planting AS, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors. Br J Cancer 1996; 73 (12): 1569-75
-
(1996)
Br J Cancer
, vol.73
, Issue.12
, pp. 1569-1575
-
-
Schellens, J.H.M.1
Ma, J.2
Planting, A.S.3
-
77
-
-
0031940674
-
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
-
Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63 (1): 11-25
-
(1998)
Clin Pharmacol Ther
, vol.63
, Issue.1
, pp. 11-25
-
-
Karlsson, M.O.1
Molnar, V.2
Bergh, J.3
-
78
-
-
13344269002
-
Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
-
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77 (3): 441-51
-
(1996)
Cancer
, vol.77
, Issue.3
, pp. 441-451
-
-
Gamelin, E.C.1
Danquechin-Dorval, E.M.2
Dumesnil, Y.F.3
-
79
-
-
0024266208
-
More is better
-
Hryniuk WM. More is better. J Clin Oncol 1988; 6 (9): 1365-7
-
(1988)
J Clin Oncol
, vol.6
, Issue.9
, pp. 1365-1367
-
-
Hryniuk, W.M.1
-
80
-
-
0023101182
-
A phase I and pharmacokinetic study of hexamethylene bisacetamide (HMBA, NSC95580) administered as a five day continuous infusion
-
Egorin MJ, Sigman LM, Van Echo DA, et al. A phase I and pharmacokinetic study of hexamethylene bisacetamide (HMBA, NSC95580) administered as a five day continuous infusion. Cancer Res 1987; 47 (2): 617-23
-
(1987)
Cancer Res
, vol.47
, Issue.2
, pp. 617-623
-
-
Egorin, M.J.1
Sigman, L.M.2
Van Echo, D.A.3
-
81
-
-
0345263738
-
Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors
-
Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors [abstract]. Blood 1997; 90: 374a
-
(1997)
Blood
, vol.90
-
-
Bolinger, A.M.1
Zangwill, A.B.2
Slattery, J.T.3
-
82
-
-
0034699950
-
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial
-
Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Lancet 2000; 356: 1284-391
-
(2000)
Lancet
, vol.356
, pp. 1284-1391
-
-
Bergh, J.1
Wiklund, T.2
Erikstein, B.3
-
83
-
-
0032774739
-
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
-
Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80 (11): 1763-6
-
(1999)
Br J Cancer
, vol.80
, Issue.11
, pp. 1763-1766
-
-
Poikonen, P.1
Saarto, T.2
Lundin, J.3
-
84
-
-
0024345093
-
Pharmacokinetics of busulphan: Correlations with veno-occlusive disease in patients undergoing bone marrow transplantation
-
Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulphan: correlations with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25 (1): 55-61
-
(1989)
Cancer Chemother Pharmacol
, vol.25
, Issue.1
, pp. 55-61
-
-
Grochow, L.B.1
Jones, R.J.2
Brundrett, R.B.3
-
85
-
-
0023303814
-
Reappraisal of some dosage adjustment guidelines
-
Sulkes A, Collins JM. Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 1987; 71 (3): 229-33
-
(1987)
Cancer Treat Rep
, vol.71
, Issue.3
, pp. 229-233
-
-
Sulkes, A.1
Collins, J.M.2
-
87
-
-
0027443965
-
Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control
-
Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control. Ther Drug Monit 1993; 15 (5): 380-93
-
(1993)
Ther Drug Monit
, vol.15
, Issue.5
, pp. 380-393
-
-
Jelliffe, R.W.1
Schumitzky, A.2
Van Guilder, M.3
-
88
-
-
0022353917
-
Feedback control methods for drug dosage optimisation: Concepts, classification and clinical application
-
Vozeh S, Steimer JL. Feedback control methods for drug dosage optimisation: concepts, classification and clinical application. Clin Pharmacokinet 1985; 10 (6): 457-76
-
(1985)
Clin Pharmacokinet
, vol.10
, Issue.6
, pp. 457-476
-
-
Vozeh, S.1
Steimer, J.L.2
-
89
-
-
0031691162
-
Expanding clinical applications of population pharmacokinetic modelling
-
Minto C, Schnider T. Expanding clinical applications of population pharmacokinetic modelling. Br J Clin Pharmacol 1998; 46 (4): 321-33
-
(1998)
Br J Clin Pharmacol
, vol.46
, Issue.4
, pp. 321-333
-
-
Minto, C.1
Schnider, T.2
-
90
-
-
0031824697
-
Methodological issues in pharmacokinetic-pharmacodynamic modelling
-
Bellissant E, Sebille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35 (2): 151-66
-
(1998)
Clin Pharmacokinet
, vol.35
, Issue.2
, pp. 151-166
-
-
Bellissant, E.1
Sebille, V.2
Paintaud, G.3
-
92
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
93
-
-
0003506753
-
-
Bethesda (MD): National Cancer Institute, Division of Cancer Treatment
-
Guidelines for reporting of adverse drug reactions. Bethesda (MD): National Cancer Institute, Division of Cancer Treatment, 1988
-
(1988)
Guidelines for Reporting of Adverse Drug Reactions
-
-
-
94
-
-
0026580927
-
Mw/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
-
Proost JH, Meijer DKF. Mw/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22 (3): 155-63
-
(1992)
Comput Biol Med
, vol.22
, Issue.3
, pp. 155-163
-
-
Proost, J.H.1
Meijer, D.K.F.2
-
95
-
-
0033823462
-
Plasma concentration monitoring of busulphan: Does it improve clinical outcome?
-
McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulphan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39 (2): 155-65
-
(2000)
Clin Pharmacokinet
, vol.39
, Issue.2
, pp. 155-165
-
-
McCune, J.S.1
Gibbs, J.P.2
Slattery, J.T.3
-
96
-
-
0031711811
-
Therapeutic monitoring of busulphan in hematopoietic stem cell transplantation
-
Slattery JT, Risler LJ. Therapeutic monitoring of busulphan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20 (5): 543-9
-
(1998)
Ther Drug Monit
, vol.20
, Issue.5
, pp. 543-549
-
-
Slattery, J.T.1
Risler, L.J.2
-
97
-
-
0024440650
-
Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
-
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 (11): 1748-56
-
(1989)
J Clin Oncol
, vol.7
, Issue.11
, pp. 1748-1756
-
-
Calvert, A.H.1
Newell, D.R.2
Gumbrell, L.A.3
-
98
-
-
0022379952
-
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedi- carboxylatoplatinum
-
Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedi-carboxylatoplatinum. Cancer Res 1985; 45: 6502-6
-
(1985)
Cancer Res
, vol.45
, pp. 6502-6506
-
-
Egorin, M.J.1
Van Echo, D.A.2
Olman, E.A.3
-
99
-
-
0028936713
-
Prediction of carboplatin clearance from standard morphological and biological patient characteristics
-
Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87 (8): 573-80
-
(1995)
J Natl Cancer Inst
, vol.87
, Issue.8
, pp. 573-580
-
-
Chatelut, E.1
Canal, P.2
Brunner, V.3
-
100
-
-
0027488001
-
Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula
-
Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 11 (12): 2314-23
-
(1993)
J Clin Oncol
, vol.11
, Issue.12
, pp. 2314-2323
-
-
Newell, D.R.1
Pearson, A.D.2
Balmanno, K.3
-
101
-
-
0033015578
-
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer: Status of the art
-
Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer: status of the art. Clin Rev Oncol Hematol 1999; 30 (1): 71-9
-
(1999)
Clin Rev Oncol Hematol
, vol.30
, Issue.1
, pp. 71-79
-
-
Gamelin, E.1
Boisdron-Celle, M.2
-
102
-
-
0027980646
-
Patient characteristics associated with high-risk methotrexate concentrations and toxicity
-
Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12 (8): 1667-72
-
(1994)
J Clin Oncol
, vol.12
, Issue.8
, pp. 1667-1672
-
-
Relling, M.V.1
Fairclough, D.2
Ayers, D.3
-
103
-
-
17644399981
-
Pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high dose chemotherapy
-
De Jonge ME, Huitema ADR, Van Dam SM, et al. Pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high dose chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 562
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 562
-
-
De Jonge, M.E.1
Huitema, A.D.R.2
Van Dam, S.M.3
-
104
-
-
0036230253
-
Cancer genetics and their application to individualized medicine
-
Liefers GJ, Tollenaar RAEM. Cancer genetics and their application to individualized medicine. Eur J Cancer 2002; 38 (7): 872-9
-
(2002)
Eur J Cancer
, vol.38
, Issue.7
, pp. 872-879
-
-
Liefers, G.J.1
Tollenaar, R.A.E.M.2
|